Aspirin and the Prevention of Experimental Arterial Thrombosis: Difficulty in Establishing Unequivocal Effectiveness

Summary

A trial of the efficacy of aspirin in the prevention of thrombotic occlusion of an “aortic loop” in rats was made simultaneously by two experimental surgeons. A relatively large dose of aspirin (80-100 mg/kg/day) was used, starting two days before operation. It appeared that aspirin was of limited benefit, reducing thrombotic occlusions by about 17% seven days after the insertion of the loop into the abdominal aorta. Although the average occlusion time was prolonged by about 17% in aspirin-treated animals, the separate trials gave no conclusive result. When the data from both operators were pooled, a statistically significant protection by aspirin was apparent (p = 0.02), by a two-tailed Student’s t test. However, on using the powerful non-parametric randomization test, the occlusion times in control and aspirin-treated groups appeared not statistically different (p = 0.07). No significant difference was also found between control and treated groups when data were analyzed by X² test. Independently of the statistical analysis, these data are quite similar to those obtained from aspirin trials in men surviving myocardial infarction. This finding points to the usefulness of the aorta loop as an animal model for arterial thrombosis.

Keywords

Aspirin - Clinical trials - Statistics - Experimental thrombosis

• References

• 1 Hornstra G, Vendelmans-Starrenburg A. Induction of experimental arterial occlusive thrombi in rats. Atherosclerosis 1973; 17: 369-382
• 2 Hornstra G, Dietary Fats. Prostanoids and Arterial Thrombosis. The Hague: Martinus Nijhoff Publ 1982; 46-51
• 3 Reyers I, Mussoni L, Donati MB, de Gaetano G. Severe thrombocytopenia delays but does not prevent the occlusion of an arterial prosthesis in rats. Thromb Haemostas 1981; 46: 558-60
• 4 Hornstra G, Vergroesen AJ. The effects of linoleic acidand prostaglandin Et on arterialthrombosis. Acta Biol Med Germ 1976; 35: 1065-1068
• 5 Reyers I, Mussoni L, Donati MB, de Gaetano G. Failure of aspirin at different doses to modify experimentalthrombosis in rats. Thromb Res 1980; 18: 669-674
• 6 Editorial: Aspirin after myocardial infarction. Lancet 1980; 1: 1172-1173
• 7 Majerus PW. Arachidonate metabolism in vascular disorders. J Clin Invest 1983; 72: 1521-1525
• 8 Recchia M, Rocchetti M. The simulated randomization test. Computer Progr Biomed 1982; 15: 111-116
• 9 de Gaetano G, Cerletti C, Bertele V. Pharmacology of antiplateletdrugs and clinical trials on thrombosis prevention: A difficult link. Lancet 1982; 2: 974-977
• 10 Marcus AJ. Aspirin as an antithromboticmedication. N Engl J Med 1983; 309: 1515-1517
• 11 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
• 12 FitzGerald GA, Oates JA, Hawiger J. et al Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronicadministration of aspirin in man. J Clin Invest 1983; 71: 676-688
• 13 Mitchell JRA. Prostacyclin-powerful, yes: but is it useful?. Br Med J 1983; 287: 1824-1826
• 14 Hornstra G, Haddeman E, Kloeze J, Verschuren PM. Dietary-fat-induced changes in the formation of prostanoids of the 2 and 3 series in relation to arterial thrombosis (rat) and atherosclerosis (rabbit). Adv Prost Thrombox Leukotr Res 1983; 12: 193-202
• 15 Chesebro JH, Fuster V, Elveback LR. et al Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. N Engl J Med 1984; 310: 209-214
• 16 Reyers I, de Gaetano G, Donati MB. Protective effect of warfarin in arterial thrombosis: Evidence from a vascular prosthesis model in rats. Thromb Haemostas 1983; 50: 821-823
• 17 Hornstra G. Dietary fats and arterial thrombosis. Thesis, Ryksuniver-siteit Limburg, Maastricht, The Netherlands. 1980